Clustering of hepatitis C virus antibody positivity within households and communities in Punjab, India.
Epidemiology
hepatitis C
serosurvey
statistics
Journal
Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737
Informations de publication
Date de publication:
07 10 2019
07 10 2019
Historique:
entrez:
8
10
2019
pubmed:
8
10
2019
medline:
25
3
2020
Statut:
epublish
Résumé
To better understand hepatitis C virus (HCV) epidemiology in Punjab state, India, we estimated the distribution of HCV antibody positivity (anti-HCV+) using a 2013-2014 HCV household seroprevalence survey. Household anti-HCV+ clustering was investigated (a) by individual-level multivariable logistic regression, and (b) comparing the observed frequency of households with multiple anti-HCV+ persons against the expected, simulated frequency assuming anti-HCV+ persons are randomly distributed. Village/ward-level clustering was investigated similarly. We estimated household-level associations between exposures and the number of anti-HCV+ members in a household (N = 1593 households) using multivariable ordered logistic regression. Anti-HCV+ prevalence was 3.6% (95% confidence interval 3.0-4.2%). Individual-level regression (N = 5543 participants) found an odds ratio of 3.19 (2.25-4.50) for someone being anti-HCV+ if another household member was anti-HCV+. Thirty households surveyed had ⩾2 anti-HCV+ members, whereas 0/1000 (P < 0.001) simulations had ⩾30 such households. Excess village-level clustering was evident: 10 villages had ⩾6 anti-HCV+ members, occurring in 31/1000 simulations (P = 0.031). The household-level model indicated the number of household members, living in southern Punjab, lower socio-economic score, and a higher proportion having ever used opium/bhuki were associated with a household's number of anti-HCV+ members. Anti-HCV+ clusters within households and villages in Punjab, India. These data should be used to inform screening efforts.
Identifiants
pubmed: 31587676
doi: 10.1017/S0950268819001705
pii: S0950268819001705
pmc: PMC6805795
doi:
Substances chimiques
Hepatitis C Antibodies
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e283Commentaires et corrections
Type : CommentIn
Références
Hepat Med. 2017 Jun 14;9:27-33
pubmed: 28652827
J Gastroenterol Hepatol. 2019 Feb;34(2):321-329
pubmed: 30176181
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Liver Int. 2011 Jul;31 Suppl 2:61-80
pubmed: 21651703
PLoS One. 2017 May 5;12(5):e0177022
pubmed: 28475637
BMJ. 2011 Mar 22;342:d1694
pubmed: 21427048
PLoS One. 2012;7(12):e51194
pubmed: 23236452
J Clin Exp Hepatol. 2016 Sep;6(3):224-232
pubmed: 27746619
J Viral Hepat. 2000 Mar;7(2):93-103
pubmed: 10760039
Int J STD AIDS. 2014 Jul;25(8):596-606
pubmed: 24352120
J Korean Med Sci. 1994 Dec;9(6):444-9
pubmed: 7786439
Eur J Epidemiol. 1996 Feb;12(1):45-50
pubmed: 8817177
Pediatr Infect Dis J. 1994 Oct;13(10):886-9
pubmed: 7854888
J Infect Public Health. 2014 Jul-Aug;7(4):345-55
pubmed: 24861642
Epidemiol Infect. 1999 Dec;123(3):515-8
pubmed: 10694166
Crit Rev Microbiol. 2018 Mar;44(2):143-160
pubmed: 28539069
Eur J Epidemiol. 1999 Feb;15(2):125-32
pubmed: 10204641
J Urban Health. 2013 Aug;90(4):699-716
pubmed: 22733170
Am J Trop Med Hyg. 2017 Dec;97(6):1920-1928
pubmed: 29141707
J Neuroimmune Pharmacol. 2010 Dec;5(4):496-506
pubmed: 20559752
Gastroenterol Hepatol Bed Bench. 2016 Fall;9(4):250-258
pubmed: 27895850
J Med Virol. 2013 Apr;85(4):608-14
pubmed: 23417615
World J Gastroenterol. 2016 Jan 28;22(4):1684-700
pubmed: 26819533
PLoS One. 2018 Jul 26;13(7):e0200461
pubmed: 30048454
World J Hepatol. 2015 Sep 28;7(21):2323-30
pubmed: 26413221
Int J Epidemiol. 1998 Jun;27(3):525-9
pubmed: 9698147